Herpes encephalitis happens when the herpes simplex virus, usually HSV-1 (the type that causes cold sores), travels along nerves from the face into the brain and triggers a dangerous inflammatory infection. About two-thirds of cases come from reactivation of a virus already living dormant in the body, not from a brand-new infection. The remaining one-third occur during a first-time herpes infection. This makes herpes encephalitis unusual: most people who develop it have carried the virus for years without any brain involvement.
How the Virus Reaches the Brain
HSV-1 typically enters the body through mucous membranes in the mouth or eyes. After that initial infection, the virus travels backward along nerve fibers to reach clusters of nerve cell bodies called ganglia, where it goes dormant. The two main nerve pathways it uses are the trigeminal nerve (which runs from the face to the brainstem) and the olfactory nerve (which connects the nasal cavity directly to the brain).
In most people, the virus stays quietly dormant in these nerve clusters for life, occasionally reactivating to cause a cold sore and nothing more. In rare cases, instead of stopping at the nerve cluster, the virus continues traveling deeper into the brain itself. Once there, it causes direct damage to brain tissue and triggers an intense immune response that compounds the destruction. The virus has a strong preference for the temporal lobes, the regions on either side of the brain involved in memory, language, and emotion. This is likely because the trigeminal and olfactory nerves connect to areas near or within the temporal lobes.
Primary Infection vs. Reactivation
In roughly one-third of herpes encephalitis cases, the brain infection happens during a person’s very first exposure to HSV. This is more common in children and young adults who haven’t yet built any immune defense against the virus. The virus enters through the mouth or nose and, rather than settling quietly into dormancy, pushes past the peripheral nerves into the central nervous system.
The other two-thirds of cases happen in people who already carry the virus. In these patients, blood tests confirm prior HSV infection, meaning the virus had been dormant in the olfactory bulb, trigeminal ganglion, or possibly in the brain tissue itself. Something triggers reactivation, and instead of producing a cold sore on the lip, the virus migrates inward toward the brain. What exactly causes this inward reactivation in certain people remains poorly understood, but immune suppression, stress, and genetic factors all play a role.
Neonatal Herpes Encephalitis
Newborns can develop herpes encephalitis through a different route entirely. HSV is most often transmitted to a baby during delivery, through contact with the mother’s infected genital tract or vaginal fluid. In rarer cases, the virus can cross the placenta before birth or spread after delivery from caregivers or family members. Signs of brain infection in a newborn typically appear 6 to 12 days after delivery, showing up as lethargy, poor feeding, irritability, tremors, or seizures.
One complicating factor is that many mothers who pass the virus to their babies have no visible symptoms at the time of delivery. Women with newly acquired genital herpes pose the highest risk because they haven’t yet developed antibodies that could offer the baby some protection.
Why Only Some People Develop Brain Infection
HSV-1 is extraordinarily common. Roughly half to two-thirds of the global adult population carries it. Yet herpes encephalitis is rare, affecting an estimated 2 to 4 people per million each year. So something specific must go wrong for the virus to breach the brain.
Research into children who develop herpes encephalitis has pointed to defects in a part of the innate immune system called the TLR3 signaling pathway. TLR3 is a sensor inside cells that detects viral genetic material and triggers production of interferons, the proteins that form the body’s first line of antiviral defense. In a study of 120 patients with herpes encephalitis, about 5% carried mutations in the TLR3 gene. Other patients had defects in related immune signaling genes. These findings suggest that some people are born with subtle gaps in the specific immune pathway that normally keeps HSV confined to the peripheral nerves.
Beyond genetics, anything that weakens immune surveillance can raise risk. This includes immune-suppressing medications, certain cancers, and conditions that impair the body’s ability to keep dormant viruses in check. But many patients who develop herpes encephalitis have no obvious immune deficiency at all, which is part of what makes the condition so unpredictable.
What Herpes Encephalitis Looks Like
The infection typically begins with fever and headache, symptoms that could easily be mistaken for the flu. Within days, it progresses to neurological changes that signal something far more serious. The most common features, based on clinical data, are:
- Altered consciousness (97% of patients), ranging from confusion to coma
- Fever (92%)
- Headache (81%)
- Psychiatric symptoms (71%), including personality changes, agitation, or hallucinations
- Seizures (67%)
- Difficulty speaking (76%)
- Weakness on one side of the body (33% to 38%)
- Memory loss (24%)
Because the virus targets the temporal lobes, personality changes and speech problems are hallmarks that help distinguish herpes encephalitis from other types of brain infection. The progression from “bad headache with a fever” to confusion and seizures can happen over just a few days, which is why speed of diagnosis matters enormously.
How Outcomes Depend on Timing
Before antiviral treatment existed, herpes encephalitis killed up to 70% of the people who developed it. The introduction of intravenous antiviral therapy in the mid-1980s brought that six-month mortality rate down to roughly 20%. Even so, with current treatment and early diagnosis, the mortality rate still sits around 30%. Only about 40% of patients recover to their previous level of functioning.
The gap between survival and full recovery reflects the damage the virus does to temporal lobe tissue. Survivors frequently deal with lasting problems in memory, language, and behavior. The earlier treatment begins, the less destruction occurs, which is why the initial hours after symptom onset carry so much weight. Every delay in starting antiviral therapy allows the infection to spread further into vulnerable brain tissue.